EVAXION BIOTECH A/S |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.18 USD | +1.46% |
|
-3.02% | -39.04% |
| 04-26 | European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading, End Week Up 3.4% | MT |
| 04-17 | Evaxion Announces Phase 2 Clinical Trial Update | CI |
| Sales 2024 * | 6.27M 502M | Sales 2025 * | 18.26M 1.46B | Capitalization | 22.62M 1.81B |
|---|---|---|---|---|---|
| Net income 2024 * | -11M -881M | Net income 2025 * | -3M -240M | EV / Sales 2024 * | 3.61 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.24 x |
| P/E ratio 2024 * |
-3.01
x | P/E ratio 2025 * |
-2.12
x | Employees | 49 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 83.4% |
More Fundamentals
* Assessed data
More news
Latest transcript on Evaxion Biotech A/S
More recommendations
More press releases
More news
| 1 day | +1.46% | ||
| 1 week | -3.02% | ||
| Current month | +30.62% | ||
| 1 month | +33.55% | ||
| 3 months | -43.36% | ||
| 6 months | -49.02% | ||
| Current year | -39.04% |
1 week
3.85
4.36
1 month
3.004.41
Current year
2.8213.61
1 year
2.8218.50
3 years
2.82250.40
5 years
2.82250.40
10 years
2.82250.40
| Managers | Title | Age | Since |
|---|---|---|---|
Andreas Mattsson
FOU | Founder | - | 10/08/08 |
Niels Møller
FOU | Founder | 46 | 10/08/08 |
| Chief Executive Officer | 52 | 28/08/23 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 54 | 31/12/17 | |
Lars Holtug
BRD | Director/Board Member | 66 | 24/05/21 |
Marianne Søgaard
CHM | Chairman | 56 | 31/12/17 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 4.18 | +1.46% | 25,104 |
| 25/04/24 | 4.12 | -0.24% | 7,185 |
| 24/04/24 | 4.13 | -0.24% | 10,156 |
| 23/04/24 | 4.14 | -1.19% | 25,028 |
| 22/04/24 | 4.19 | -2.78% | 9,891 |
Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm
More quotes
Evaxion Biotech A/S is a Denmark-based clinical-stage biotechnology company, which specializes in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases. The Company decodes the human immune system to discover and develop immunotherapies to treat cancer and infectious diseases. Based on AI-immunology core technology, Evaxion is developing a pipeline of product candidates. In addition, Evaxion develops portfolio of vaccines to prevent bacterial and viral infections.
Calendar
08/05/2024
- Q1 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
4.18
USD
Average target price
11.75
USD
Spread / Average Target
+181.10%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -39.04% | 21.8M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- EVAX Stock
